Tomas N. Dam

Nykobing Falster, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Comparative 2-year drug survival of bimekizumab and brodalumab in second-line treatment of psoriasis.

Comparative 2-year drug survival of bimekizumab and brodalumab in second-line treatment of psoriasis.

Journal: Journal of the American Academy of Dermatology

Published: January 14, 2026

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.

Journal: JAMA dermatology

Published: January 07, 2026

Changes in Drug Survival of Adalimumab Over Time in Patients with Psoriasis - A Nationwide Cohort Study.

Changes in Drug Survival of Adalimumab Over Time in Patients with Psoriasis - A Nationwide Cohort Study.

Journal: Clinical and experimental dermatology

Published: September 15, 2025

Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study.

Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study.

Journal: Clinical and experimental dermatology

Published: September 15, 2025

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study.

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study.

Journal: Acta dermato-venereologica

Published: November 25, 2024

Medical specialists' use and opinion of video consultation in Denmark: a survey study.

Medical specialists' use and opinion of video consultation in Denmark: a survey study.

Journal: BMC health services research

Published: July 20, 2023

Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.

Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.

Journal: Acta dermato-venereologica

Published: May 09, 2023

Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study.

Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study.

Journal: Journal of the American Academy of Dermatology

Published: November 28, 2022

Machine learning model for predicting outcomes of biologic therapy in psoriasis.

Machine learning model for predicting outcomes of biologic therapy in psoriasis.

Journal: Journal of the American Academy of Dermatology

Published: April 30, 2022

Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.

Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 22, 2021

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.

Journal: Acta dermato-venereologica

Published: October 13, 2021

Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.

Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.

Journal: JAMA dermatology

Published: April 07, 2021

Showing 1-12 of 29

Last Updated: 09/26/2026